# A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

> **NCT02601950** · PHASE2 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 267 (actual)

## Conditions studied

- Malignant Rhabdoid Tumors (MRT)
- Rhabdoid Tumors of the Kidney (RTK)
- Atypical Teratoid Rhabdoid Tumors (ATRT)
- Selected Tumors With Rhabdoid Features
- Synovial Sarcoma
- INI1-negative Tumors
- Malignant Rhabdoid Tumor of Ovary
- Renal Medullary Carcinoma
- Epithelioid Sarcoma
- Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)
- Any Solid Tumor With an EZH2 GOF Mutation

## Interventions

- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT02601950
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-22
- **Primary completion:** 2024-02-26
- **Final completion:** 2024-02-26
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601950, "A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02601950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*